Coherus BioSciences Announces New Employment Inducement Grants
July 21, 2023 17:30 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., July 21, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 20, 2023, the compensation committee...
Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
July 20, 2023 16:04 ET
|
Coherus BioSciences, Inc.
– Recognized biopharma commercialization and market access leader to support Coherus’ strategic vision and multiple product launches – REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) --...
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
July 13, 2023 08:30 ET
|
Coherus BioSciences, Inc.
First formal distribution agreement for YUSIMRY™, a biosimilar of Humira®, at $995 per carton (two 40 mg/0.8 mL autoinjectors) representing a discount of more than 85% compared to HumiraInnovative...
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
July 03, 2023 08:30 ET
|
Coherus BioSciences, Inc.
–$995 per carton (two 40 mg/0.8 mL autoinjectors) represents a discount of more than 85% compared to Humira® – – YUSIMRY™ meets high unmet need by providing patients, employers, physicians and...
Coherus BioSciences Announces New Employment Inducement Grants
June 26, 2023 21:08 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 20, 2023, the compensation committee...
Coherus to Acquire Surface Oncology
June 16, 2023 07:01 ET
|
Coherus BioSciences, Inc.
– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – ...
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
June 05, 2023 17:30 ET
|
Coherus BioSciences, Inc.
– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are approved for NPC in...
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
June 01, 2023 08:33 ET
|
Coherus BioSciences, Inc.
– YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company – – YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and...
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
June 01, 2023 08:30 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the company plans to launch YUSIMRY™ (adalimumab-aqvh) in July 2023*...
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
May 22, 2023 08:30 ET
|
Coherus BioSciences, Inc.
– UDENYCA® AI is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home – – UDENYCA® AI fulfills high unmet need...